← All companies

GLUE

Monte Rosa Therapeutics, Inc.

GLUE Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗

$15.38

-7.30 -32.19%

Key statistics

from XBRL data in SEC filings

Market cap

$1.30B

Revenue (TTM)

$43.0M

Net income (TTM)

-$130M

EPS (TTM)

$-9.63

P/E ratio

—

Dividend yield

—

Free cash flow

-$27.5M

Cash

$160M

Total assets

$736M

Gross margin

—

52-week range

$4.12 – $25.77

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Shareholder vote results Jun 11, 2026 10-Q Quarter ended 2026-03-31 May 7, 2026 8-K Results of operations (earnings release) May 7, 2026 10-K Fiscal year ended 2025-12-31 Mar 17, 2026 8-K Results of operations (earnings release) Mar 17, 2026 8-K Director or officer change Feb 10, 2026 8-K Entered a material agreement; Other events Jan 9, 2026 8-K Other events Jan 7, 2026 8-K Regulation FD disclosure; Other events Jan 7, 2026 8-K Regulation FD disclosure; Other events Dec 16, 2025 10-Q Quarter ended 2025-09-30 Nov 6, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Nov 6, 2025 8-K Entered a material agreement; Regulation FD disclosure Sep 15, 2025 10-Q Quarter ended 2025-06-30 Aug 7, 2025 8-K Results of operations (earnings release) Aug 7, 2025 8-K Shareholder vote results Jun 13, 2025 10-Q Quarter ended 2025-03-31 May 8, 2025 8-K Results of operations (earnings release); Regulation FD disclosure May 8, 2025 10-K Fiscal year ended 2024-12-31 Mar 20, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Mar 20, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Jan 10, 2025 8-K Director or officer change Dec 13, 2024 8-K Regulation FD disclosure; Other events Dec 5, 2024 10-Q Quarter ended 2024-09-30 Nov 7, 2024 8-K Results of operations (earnings release) Nov 7, 2024 8-K Entered a material agreement; Regulation FD disclosure Oct 28, 2024 10-Q Quarter ended 2024-06-30 Aug 8, 2024 8-K Results of operations (earnings release) Aug 8, 2024 8-K Regulation FD disclosure Jun 27, 2024 8-K Shareholder vote results Jun 12, 2024 8-K Director or officer change; Regulation FD disclosure May 30, 2024 8-K Entered a material agreement May 16, 2024 10-Q Quarter ended 2024-03-31 May 9, 2024 8-K Results of operations (earnings release); Regulation FD disclosure May 9, 2024 8-K Director or officer change; Regulation FD disclosure May 2, 2024 10-K Fiscal year ended 2023-12-31 Mar 14, 2024 8-K Results of operations (earnings release); Regulation FD disclosure Mar 14, 2024 8-K Regulation FD disclosure Jan 8, 2024 10-Q Quarter ended 2023-09-30 Nov 9, 2023 8-K Results of operations (earnings release) Nov 9, 2023